Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) Senior Officer Robert Christopher Andrade acquired 8,220 shares of Fennec Pharmaceuticals stock in a transaction that occurred on Monday, June 2nd. The shares were purchased at an average price of C$6.99 per share, with a total value of C$57,433.14.
Fennec Pharmaceuticals Stock Performance
TSE:FRX traded up C$0.46 during mid-day trading on Friday, hitting C$11.79. 726 shares of the company traded hands, compared to its average volume of 1,198. The stock's fifty day moving average price is C$8.77 and its 200-day moving average price is C$8.92. Fennec Pharmaceuticals Inc. has a one year low of C$5.65 and a one year high of C$11.79. The company has a quick ratio of 10.17, a current ratio of 7.80 and a debt-to-equity ratio of -620.83. The firm has a market cap of C$227.37 million, a price-to-earnings ratio of -199.72 and a beta of 0.25.
Fennec Pharmaceuticals Company Profile
(
Get Free Report)
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Further Reading
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
